- Home
- GNPX vs ELAB Comparison
GNPX vs ELAB Comparison
Compare GNPX & ELAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNPX | ELAB |
|---|---|---|
| Founded | 2009 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 4.0M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | GNPX | ELAB |
|---|---|---|
| Price | $1.35 | $3.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 272.2K | ★ 8.2M |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $0.66 |
| 52 Week High | $12.97 | $15.00 |
Technical Indicators
Market Signals| Indicator | GNPX | ELAB |
|---|---|---|
| Relative Strength Index (RSI) | 25.92 | 49.01 |
| Support Level | $0.18 | $1.71 |
| Resistance Level | $2.12 | $4.61 |
| Average True Range (ATR) | 0.12 | 1.59 |
| MACD | -0.05 | 0.08 |
| Stochastic Oscillator | 6.57 | 13.60 |
Price Performance
Historical ComparisonAbout GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.